National Registry of Rare Kidney Diseases

NCT06065852 | Recruiting

• 1 other identifier: RaDaR
• Study Type: observational
• Target: 35,000
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research. The purpose of this research is to:

• Develop Clinical Guidelines for specific rare kidney diseases. These are written recommendations on how to diagnose and treat a medical condition.
• Audit treatments and outcomes. An audit makes checks to see if what should be done is being done and asks if it could be done better.
• Further the development of future treatments. Participants will be invited to participate on clinical trials and other studies. The registry has the capacity to feedback relevant information to patients and in conjunction with Patient Knows Best (Home - Patients Know Best), allows patients to provide information themselves, including their own reported quality of life and outcome measures.

Conditions

Adenine Phosphoribosyltransferase Deficiency; AH Amyloidosis; AHL Amyloidosis; AL Amyloidosis; Alport Syndrome; Atypical Hemolytic Uremic Syndrome; Autoimmune Distal Renal Tubular Acidosis; Autosomal Recessive Proximal Renal Tubular Acidosis; Autosomal Recessive Distal Renal Tubular Acidosis; Autosomal Dominant Polycystic Kidney Disease; Autosomal Recessive Polycystic Kidney Disease; Bartter Syndrome; BK Nephropathy; C3 Glomerulopathy With Monoclonal Gammopathy; C3 Glomerulopathy; Calciphylaxis; Crystalglobulinaemia; Crystal-storing Histiocytosis; Cystinosis; Cystinuria; Dense Deposit Disease; Dent Disease; Denys-Drash Syndrome; Dominant Hypophosphataemia With Nephrolithiasis and/or Osteoporosis; Drug Induced Fanconi Syndrome; Drug-Induced Hypomagnesemia; Drug-Induced Nephrogenic Diabetes Insipidus; Epilepsy, Ataxia, Sensorineural Deafness and Tubulopathy; Fabry Disease; Familial Hypomagnesemia With Hypercalciuria and Nephrocalcinosis; Familial Primary Hypomagnesemia With Hypocalcuria; Familial Primary Hypomagnesaemia With Normocalciuria; Familial Renal Glucosuria; Fanconi Renotubular Syndrome 1; Fanconi Renotubular Syndrome 2; Fanconi Renotubular Syndrome 3; Fibrillary Glomerulonephritis; Fibromuscular Dysplasia; Focal Segmental Glomerulosclerosis; Generalised Pseudohypoaldosteronism Type 1; Gitelman Syndrome; Heavy-Metal-Induced Fanconi Syndrome; Hepatocyte Nuclear Factor 1-Beta-Associated Monogenic Diabetes; Hereditary Renal Hypouricemia; Hereditary Hypophosphatemic Rickets With Hypercalciuria; Hyperuricaemic Nephropathy; IgA Nephropathy; Immunotactoid Glomerulonephritis With Organised Microtubular Mononoclonal Immunoglobulin Deposits; Inherited Renal Cancer Syndromes; Intracapillary Monoclonal IgM Without Cryoglobulin; Intraglomerular/Capillary Lymphoma/Leukaemia; Isolated Autosomal Dominant Hypomagnesaemia Glaudemans Type; Liddle Syndrome; Light Chain Cast Nephropathy; Light Chain Proximal Tubulopathy Without Crystals; Light Chain Proximal Tubulopathy With Crystals; Lowe Syndrome; Membranous Nephropathy; Membranoproliferative Glomerulonephritis; Medullary Cystic Kidney Disease; Minimal Change Nephropathy; Mitochondrial Disease Of The Kidney; Monoclonal Immunoglobulin Deposition Disease; Nail Patella Syndrome; Nephrogenic Diabetes Insipidus; Nephrogenic Syndrome of Inappropriate Antidiuresis; Nephronophthisis; Primary Hypomagnesemia With Secondary Hypocalcemia; Primary Hyperoxaluria; Proliferative Glomerulonephritis With Monoclonal IgG Deposits; Proximal Tubulopathy Without Crystals; Pseudohypoaldosteronism Type 1, 2A-2E; Pure Red Cell Aplasia; Retroperitoneal Fibrosis; Sickle Cell Nephropathy; Shiga Toxin Associated Haemolytic Uraemic Syndrome; Steroid Resistant Nephrotic Syndrome; Steroid-Sensitive Nephrotic Syndrome; Thin Basement Membrane Nephropathy; Thrombotic Microangiopathy With Monoclonal Gammopathy; Type 1 Cryoglobulinaemic Glomerulonephritis; Tuberous Sclerosis; Unclassified Monoclonal Gammopathy Of Renal Significance; Vasculitis

Outcome Measures

Primary Outcomes (1)

• Facilitate translational and epidemiological research

  Setting up and maintaining a comprehensive clinical database in partnership with Rare Disease Groups.

  2009-2039

Study Arms (31)

Alport Syndrome Rare Disease Group

The evidence base in Alport Syndrome is small, but there is a very important education gap which it is the group's priority. Our first priorities are to assemble and make available clear information for clinicians caring for patients, as well as for patients themselves including making it clear for Commissioners 'Who should be tested' establish contact details for advice on specific issues make it clear how to approach the group for clinical advice and how to enrol patients in the group. In time this may lead to specialised regional clinics, made possible by recruiting more interested clinicians as the project develops.

APRT Deficiency Rare Disease Group

Aims: 1. To collect clinical data on patients with APRT Deficiency in a Registry. This will allow us to: study the causes, natural history and outcome of the condition develop patient cohorts for future studies 2. To collect biological samples for future studies in a Biobank. This will allow us to: identify factors influencing the course of APRT Deficiency determine the role of various genes 3. To develop new methods to measure urinary purine excretion. This will improve tools that allow us to: study the effectiveness of pharmacological and dietary interventions identify factors influencing the course of the condition 4. To work with patient organisations, health care professionals and researchers: to enhance the education and training aspect of this project to develop strategies to increase the awareness and early detection of APRT Deficiency and improve patient outcomes.

ARPKD & NPHP Rare Disease Group

Aims: The Autosomal Recessive Polycystic Kidney Disease (ARPKD)/Nephronophthisis (NPHP) Rare Disease Group (RDG) aims to: Develop and advocate best practice guidelines for the treatment of ARPKD and NPHP Provide up-to-date, best practice patient information and group support Support research into basic science, genetic, translational, psychosocial and clinical aspects of ARPKD and NPHP Foster collaborations with European and international groups and partner

Atypical Haemolytic Uraemic Syndrome Rare Disease Group

Aims: To establish and maintain a registry of all individuals affected by aHUS in the UK To provide information to clinicians on the investigation and management of aHUS To provide information to affected individuals and their families on aHUS To facilitate collaborative research into all aspects of aHUS

Autosomal Dominant Polycystic Kidney Disease Rare Disease Group

Aims: To develop the ADPKD RaDaR registry To develop best practice guidelines in regards to the treatment of ADPKD To provide better patient information and support To develop international collaborations to enable the above aims To support research, in collaboration with international groups, into basic science, disease progression models and clinical trials

Autosomal Dominant Tubulointerstitial Kidney Disease Rare Disease Group

The group was established as part of the RaDaR initiative, in light of the increasing numbers of families being identified with this syndrome and following the pioneering work undertaken by Dr Anne Simmonds and others in the Purine Laboratory at Guy's Hospital, London.

BK Nephropathy Rare Disease Group

The BK Nephropathy (BKN) Rare Disease Group aims to: collate contemporary information from UK kidney transplant recipients with BK Nephropathy use this information to develop current and relevant information for patients disseminate this information to the renal and transplant communities establish a national consensus to identify recipients at high risk of developing BK Nephropathy develop a recommendation for the optimal screening frequency for the presence of BK viraemia by PCR of peripheral blood produce guidance on the modification of immunosuppressive regimens and use of additional agents to treat BK Nephropathy develop a strategy for patient recruitment to observational and interventional clinical trials

Calciphylaxis rare Disease Group

The Calciphylaxis Rare Disease Group aims to: Develop a comprehensive clinical database of Calciphylaxis patients via the RaDaR Rare Disease Registry Collaborate with international registries, particularly the German registry Form an expert panel of interested clinicians to review future clinical trials and research programmes Develop diagnostic and treatment algorithms

CKD due to Genetic Factors in people of African ancestry Rare Disease Group

People of African or Afro-Caribbean ancestry are five times more likely to have kidney disease. They also develop kidney failure when they are about ten years younger than white people. The connection between ethnicity and kidney disease is complex. There have been some new scientific discoveries which may help us to begin to understand the cause of this problem and develop treatments, but much more work is needed. This group will allow us to find lots of people with African or Afro-Caribbean ancestry with CKD living in the UK that can take part in research.

Cystinosis Rare Disease Group

Aims: To improve the care for all patients with cystinosis in the UK To collaborate with the National Designation Centres for Cystinosis To work together with Cystinosis Foundation UK and other patient groups To register every willing patient with cystinosis onto RaDaR To promote research for the benefit of patients with cystinosis, and their families To promote educational resources for patients with cystinosis, and their families

Cystinuria Rare Disease Group

To improve our understanding of kidney stone formation in Cystinuria, develop best practice in the care of patients with this condition and to develop new ways to prevent and treat Cystinuria.

Dent Disease & Lowe Syndrome Rare Disease Group

The group aims to advance our knowledge of Dent Disease and Lowe Syndrome by: establishing a registry of patients developing clinical guidelines regarding diagnosis and treatment providing a platform for clinical and molecular research into these disorders empowering affected patients and their families by facilitating contacts between patient/families and by the development of educational material

Fabry Disease Rare Disease Group

The main objectives of the Fabry Disease Rare Disease Group are to: Provide reliable information for patients and relatives regarding the condition Provide referral information for clinicians, including details about where to send samples Improve referral pathways between the relevant specialties in each geographical area e.g. cardiology and nephrology Design and implement studies to determine the burden of undiagnosed disease and make testing for Fabry more accessible nationwide Organise patient information days to promote face-to-face contact between clinicians and patients/families

Fibromuscular Dysplasia Rare Disease Group

The main objectives of the Fibromuscular Dysplasia Rare Disease Group are to: Raise awareness and provide advice about the best strategy for the diagnosis and management of this still underdiagnosed disease. Study the presentation of the disease and baseline patient demographics. Study the prevalence of different subtypes of Fibromuscular Dysplasia, the incidence and determinants of disease progression/extension and complications Develop a Register of long term impact of intervention, as part of RaDaR

Haemolytic Uraemic Syndrome Rare Disease Group

1. To identify key issues and challenges facing the field of Haemolytic Uraemic Syndrome, specifically in the development of an informatics framework within the UK 2. To stimulate and encourage industry partnerships. 3. To identify the needs and priorities for basic, clinical, translational and social research 4. To identify suitable funding opportunities and help support appropriate strategies for successful applications.

Hepatic Nuclear Factor 1B Mutation Rare Disease Group

The HNF1B rare disease group (RDG) covers all diseases associated with mutations and deletions in this gene. These include renal developmental disorders, most commonly renal cysts. The most common problem outside the kidneys is diabetes. When diabetes and renal cysts occur together this is known as the renal cysts and diabetes (RCAD) syndrome. Other clinical features may include hyperuricaemia and gout, hypomagnesaemia, abnormal liver function tests, pancreatic exocrine deficiency and genital tract malformations. We aim to increase clincians' awareness of these presentations, improve recognition and streamline diagnosis, particularly at a genetic level. To do this we are studying genetic information on patients with well-defined clinical features. We hold open meetings to inform and support patients and their families.

Hyperoxaluria Rare Disease Group

The Hyperoxaluria Rare Disease Group aims to: The Hyperoxaluria Rare Disease Group aims to: Provide up to date support for patients and their families. Increase the knowledge and understanding of Primary Hyperoxaluria and Oxalosis to improve its clinical management. Provide clinical information on dialysis and transplantation. Increase the knowledge of clinical presentation and outcome of Primary Hyperoxaluria. Foster national and international partnerships to promote scientific innovation and research in Primary Hyperoxaluria and facilitate applications for funding for research collaboration. Create a forum for UK clinical studies on Primary Hyperoxaluria, including trials with orphan drugs. Foster genotype studies on Primary Hyperoxaluria. Co-operate in order to obtain funding for research activities through industrial or public partners in order to facilitate the dissemination of the results deriving from scientific research.'

IgA Nephropathy Rare Disease Group

The IgA Nephropathy (IgAN) Rare Disease Group aims to: collate avaliable information on IgAN and develop new information for both patients and carers implement a communications strategy for the wider renal community about all aspects of the RDG's work programme develop a strategy for patient recruitment to clinical trials in IgAN

Inherited Renal Cancer Syndromes Rare Disease Group

The development of evidence based clinical care pathways in inherited RCC has been identified as a priority owing to the lack of fully commissioned screening programmes nationally. Several published expert led disease management guidelines are being evaluated. Therefore the familial RCC RDG will set as a priority the development and validation of evidence based care pathways that reflect both national and international opinion and can be adopted by NHS commissioning groups. The familial RDG will work closely with other RDGs, the Renal Registry and the Renal Association to produce advice for commissioners that relate to specific aspects of these diseases as well as more general advice that relates to rare diseases, CKD and renal replacement therapy.

Lupus Nephritis Rare Disease Group

Membranous Nephropathy Rare Disease Group

Aims: 1. To develop evidence based clinical care pathways. Current treatment for Membranous Nephropathy (MN) is based on knowledge and drugs available in the 1990's. 2. To empower and inform patients and families. 3. To audit clinical outcomes: Establish a registry of biopsy proven prevalent cases and new incident cases of both primary and secondary MN starting from Jan 2013. In total we seek to capture data on 2000 patients during the next 5 years with a minimum of one complete data return per patient per year. 4. To promote and develop research.

Mitochondrial disease affecting the kidney Rare Disease Group

This group is to promote the recognition of patients with mitochondrial disease affecting the kidney.

Monoclonal Gammopathy of Renal Significance Rare Disease Group

To promote the RaDaR registration of patients affected by Monoclonal Gammopathy of Renal Significance (MGRS) To develop standard operating procedures in regards to the treatment of Paraprotein Associated Kidney Diseases To provide better patient information and support To support research, in collaboration with international groups, into basic science, disease progression models and clinical trials

MPGN, DDD & C3 Glomerulopathy Rare Disease Group

To bring together clinicians, scientists and consumers for the purposes of: Undertaking clinical research into the causes of and treatment for MPGN and C3 glomerulopathies Promoting best clinical practice for patients with MPGN and C3 glomerulopathies Facilitating support for patients and families affected by MPGN and C3 glomerulopathies

Nephrotic Syndrome Rare Disease Group

To compile a comprehensive UK registry of childhood and adult Nephrotic Syndrome, which includes detailed clinical information, laboratory results and genetic testing information where available. The information will be available to the patients/parents, their clinicians, and, in an anonymised form, to the Nephrotic Syndrome Rare Disease Group for research purposes. To investigate the underlying cause of Nephrotic Syndrome by comprehensive genetic testing of all patients (with full informed consent), and the study of patient plasma for biomarkers of disease To inform patients about the latest research and educational advances regarding the disease To put patients in touch with recognised support groups and charities To develop treatment and investigation guidelines for clinicians and patients To enable clinical trials to be designed and carried out to further management of the disease

Pregnancy and Chronic Kidney Disease Rare Disease Group

Increasing numbers of women with chronic kidney disease (CKD) are thinking about pregnancy. It has been known for over 50 years that CKD can affect how a pregnancy progresses and that a pregnancy can have a negative effect on damaged kidneys. However, outcomes have been improving decade by decade. The group will develop care pathways for women with CKD throughout pregnancy. Specific areas of research interest include: What is the best blood pressure target during pregnancy for women with CKD? Is preconception counselling for women with CKD useful? How should we prevent blood clots during pregnancy in women with CKD? What is the effect of protein loss in the urine on pregnancies? Which women with CKD are most likely to develop pre-eclampsia? What is the best way to measure kidney function in pregnant women with CKD? What happens to mothers with CKD and their babies after pregnancy?

Pure Red Cell Aplasia Rare Disease Group

To increase awareness of Pure Red Cell Aplasia (PRCA). To streamline the diagnostic process. To investigate and implement measures to reduce the incidence of the disease. To empower affected patients in seeking help and support. To establish international collaborations to promote research into the causes and management of the disease.

Retroperitoneal Fibrosis Rare Disease Group

The Retroperitoneal Fibrosis (RPF) Rare Disease Group aims to: establish a registry of patient data and biological samples (plasma, urine, biopsy tissue) collate available information on RPF and develop new information for both patients and carers improve upon observational data in terms of the presentation, natural history and outcomes in RPF patients nationally develop multi-disciplinary consensus care pathways and clinical guidelines for RPF develop a strategy for patient recruitment to trials

Tuberous Sclerosis Rare Disease Group

There are a number of unanswered questions relating to Tuberous Sclerosis Complex (TSC), which the RDG hopes to be able to address: What is the frequency and severity of renal involvement in patients with TSC, particularly as they grow older? What is the frequency of multiple renal AMLs in individuals without other features of TSC? What is the frequency of renal impairment or renal haemorrhage in patients with renal AMLs, and how does this relate the lesion size, number and distribution? What is the frequency of bleeding or renal impairment in patients with multiple renal AMLS treated with mTOR inhibitors or other interventions? What is the frequency of impaired GFR (CKD stage 2 or higher), and what are the causes? What is the efficacy of treatment of renal AMLs in preventing bleeding and preserving GFR? What are the optional treatment regimes with mTOR inhibitors?

Tubulopathy Rare Disease Group

The newly renamed Tubulopathy Rare Disease Group, previously known as Hypokalaemic Alkaloses, has recently expanded it's inclusion criteria for RaDaR to include a large number of conditions.

Vasculitis Rare Disease Group

The Vasculitis Rare Disease Group has developed from the UK and Ireland Vasculitis registry initiative UKIVAS. The group members represent Vasculitis units across the UK and participate in Vasculitis research and care. We have a number of aims: To promote collaboration and sharing of expertise and resources in clinical research To develop guidelines for the management of Vasculitis To develop a nationwide registry of anonymized demographic, treatment and outcome data for patients with Vasculitis in the UK and Ireland To develop high quality patient and clinician information via the Rare Renal and Vasculitis UK websites To link with interested patient groups, research collaborations and industry.

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Varies for each Rare Disease Group

* Kidney Rare Disease * Paeds and adults * Eligibility differs for each rare disease group * See: https://ukkidney.org/rare-renal/recruitment

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• UK Kidney Association: lead

Study Sites (1)

Zoe Plummer

Bristol, South West, BS34 7RR, United Kingdom

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

RaDaR participants agree for their past, present and future clinical data to be used for ongoing and future research into kidney disease and related conditions. Some of this research involves the collection, processing and storage of biospecimens, including DNA. Individuals consent for this on an individual study basis.

MeSH Terms

Conditions

Adenine phosphoribosyltransferase deficiency; Immunoglobulin Light-chain Amyloidosis; Nephritis, Hereditary; Atypical Hemolytic Uremic Syndrome; Renal tubular acidosis, distal, autosomal recessive; Polycystic Kidney, Autosomal Dominant; Polycystic Kidney, Autosomal Recessive; Bartter Syndrome; Calciphylaxis; Cystinosis; Cystinuria; Glomerulonephritis, Membranoproliferative; Dent Disease; Denys-Drash Syndrome; SeSAME syndrome; Fabry Disease; Hypomagnesemia primary; Hypomagnesemia 1, Intestinal; Glycosuria, Renal; Fibromuscular Dysplasia; Glomerulosclerosis, Focal Segmental; Gitelman Syndrome; Renal cysts and diabetes syndrome; Hypophosphatemic Rickets with Hypercalciuria, Hereditary; Glomerulonephritis, IGA; Liddle Syndrome; Oculocerebrorenal Syndrome; Glomerulonephritis, Membranous; Nephronophthisis, familial juvenile; Nephrosis, Lipoid; Nail-Patella Syndrome; Diabetes Insipidus, Nephrogenic; Nephrogenic Syndrome of Inappropriate Antidiuresis; Hyperoxaluria, Primary; Pseudohypoaldosteronism; Red-Cell Aplasia, Pure; Retroperitoneal Fibrosis; Nephrotic Syndrome; Hematuria, Benign Familial; Tuberous Sclerosis; Vasculitis

Condition Hierarchy (Ancestors)

Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Amyloidosis; Proteostasis Deficiencies; Metabolic Diseases; Nutritional and Metabolic Diseases; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases; Paraproteinemias; Urogenital Abnormalities; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Nephritis; Kidney Diseases; Urologic Diseases; Male Urogenital Diseases; Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Collagen Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Hemolytic-Uremic Syndrome; Uremia; Anemia, Hemolytic; Anemia; Hematologic Diseases; Hemic and Lymphatic Diseases; Thrombotic Microangiopathies; Thrombocytopenia; Blood Platelet Disorders; Cytopenia; Polycystic Kidney Diseases; Kidney Diseases, Cystic; Abnormalities, Multiple; Ciliopathies; Genetic Diseases, Inborn; Renal Tubular Transport, Inborn Errors; Hyperaldosteronism; Adrenocortical Hyperfunction; Adrenal Gland Diseases; Endocrine System Diseases; Calcinosis; Calcium Metabolism Disorders; Lysosomal Storage Diseases; Metabolism, Inborn Errors; Renal Aminoacidurias; Glomerulonephritis; Genetic Diseases, X-Linked; Wilms Tumor; Neoplasms, Complex and Mixed; Kidney Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Neoplastic Syndromes, Hereditary; Disorder of Sex Development, 46,XY; Disorders of Sex Development; Gonadal Disorders; Sphingolipidoses; Lysosomal Storage Diseases, Nervous System; Brain Diseases, Metabolic, Inborn; Brain Diseases, Metabolic; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Cerebral Small Vessel Diseases; Cerebrovascular Disorders; Vascular Diseases; Cardiovascular Diseases; Lipidoses; Lipid Metabolism, Inborn Errors; Lipid Metabolism Disorders; Glycosuria; Urination Disorders; Glucose Metabolism Disorders; Arterial Occlusive Diseases; Autoimmune Diseases; Amino Acid Transport Disorders, Inborn; Nephrosis; Joint Diseases; Musculoskeletal Diseases; Nail Diseases; Skin Diseases; Diabetes Insipidus; Hyperoxaluria; Carbohydrate Metabolism, Inborn Errors; Fibrosis; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Hamartoma; Neoplasms, Multiple Primary; Malformations of Cortical Development, Group I; Malformations of Cortical Development; Nervous System Malformations; Neurocutaneous Syndromes; Heredodegenerative Disorders, Nervous System; Neurodegenerative Diseases

Central Study Contacts

Zoe Plummer

CONTACT

zoe.plummer@ukkidney.org

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Target Duration: 30 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 19, 2023
• First Posted: October 4, 2023
• Study Start: November 6, 2009
• Primary Completion (Estimated): December 31, 2039
• Study Completion (Estimated): December 31, 2039
• Last Updated: October 4, 2023

Record last verified: 2023-09

Locations

GB (1)